| ||The security and scientific validity of this study is the responsibility of the examine sponsor and investigators. Listing a study does not intend it has actually been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
Top of Page Study Description Study Deauthorize Arms and also Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
This is a study of pembrolizumab (MK-3475) as first-line therapy for participants through progressed gastric or gastroesophageal junction (GEJ) adenocarcinoma. Participants whose tumors expush programmed death-ligand also 1 (PD-L1) will certainly be randomly assigned to among the three therapy arms of the study: pembrolizumab as monotreatment
You are watching: Which is the superior observational study? why? choose the correct answer below.
The major research hypotheses are that pembrolizumab in combination via SOC chemotherapy is premium to SOC chemotherapy alone in terms of Progression-totally free Survival (PFS) and Overall Survival (OS) in participants via PD-L1 Incorporated Positive Score (CPS) ≥1, pembrolizumab in combination via SOC chemotherapy is premium to SOC chemotreatment alone in regards to OS in participants with PD-L1 CPS ≥10, pembrolizumab monotreatment is non-inferior to SOC chemotreatment alone in regards to OS in participants via PD-L1 CPS ≥1, and also pembrolizumab monotherapy is exceptional to SOC chemotherapy alone in terms of OS in participants through PD-L1 CPS ≥1 and also in participants through PD-L1 CPS ≥10.
|Gastric Adenocarcinoma||Biological: Pembrolizumab Drug: Cisplatin Drug: 5-FU Drug: Capecitabine Drug: Placebo||Phase 3|
As mentioned by the protocol, main and second efficacy analyses will certainly be evaluated in gastric cancer participants with PD-L1 CPS ≥1 (all participants) and also PD-L1 CPS ≥10 (OS) by comparing the pembro mono arm or pembro combo arm independently to the SOC arm.
See more: Alex Jones Alec Baldwin - Alex Jones Challenges Baldwin To 'Bare
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and also Locations More Information
|Study Type :||Interventional (Clinical Trial)|
|ActualEnrollment :||763 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Masking Description:||This research is partially blinded. The participant, examine website personnel, and the sponsor will be blinded in the pembrolizumab plus SOC chemotherapy (pembro combo) arm and the placebo plus SOC chemotreatment (SOC) arm, but not in the pembro monotreatment (mono arm) since just one type of study medication will be administered.|
|Official Title:||A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotreatment and also in Combination With Cisplatin+5-Fluorouracil Versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects With Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma|
|Actual Study Start Date :||July 31, 2015|
|Actual Key Completion Date :||March 26, 2019|
|Estimated Study Completion Date :||June 6, 2022|